# A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

> **NCT00060554** · PHASE2 · WITHDRAWN · sponsor: **Schering-Plough** · enrollment: 300 (—)

## Conditions studied

- Myocardial Infarction
- Coronary Disease

## Interventions

- **DRUG:** fondaparinux sodium
- **DRUG:** heparin
- **PROCEDURE:** percutaneous coronary intervention (PCI)

## Key facts

- **NCT ID:** NCT00060554
- **Lead sponsor:** Schering-Plough
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 300 (—)
- **Why stopped:** Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data.
- **Last updated:** 2009-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00060554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00060554, "A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00060554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*